MRV Research

Combined Adaptive and Innate Immunity Stops Tumor Growth in Severe Melanoma Models

In a new study entitled “Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2,” researchers show how combining both innate and adaptive immune strategies in immunotherapy boosts anti-tumor activity and prevents tumor re-formation. The study was published in the journal Cancer Cell.

Read More
MRV News
Melanoma News
Archive
Menu